Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2024-06-19 Regulatory Filings
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (NSE and BSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It provides details about a notice received from the Goods and Service Tax (GST) Authority regarding a demand notice (Form GST ASMT-10) for the period 2020-2021. The document states the company will respond to the notice and update the exchanges on material developments. The content is a regulatory announcement about a legal/tax matter but does not contain financial statements or detailed financial analysis. It is a compliance disclosure under SEBI regulations, not a full audit report, annual report, or earnings release. The document length is short (3242 characters), and it is primarily an announcement of a regulatory/legal notice received. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-06-19 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation of Indoco Remedies Limited' dated June 10, 2024, and is addressed to stock exchanges as per SEBI regulations. It explicitly states it is an 'Investor Presentation' and includes detailed company overview, business segments, board of directors, key management personnel, milestones, and geographical footprint. The content is typical of a presentation aimed at investors and analysts, focusing on company strategy, financial highlights, and management profiles. There is no indication that this is a full financial report, audit report, earnings release, or regulatory filing. The document length is substantial (15,000 characters), consistent with a detailed presentation. Therefore, the appropriate classification is 'Investor Presentation' (IP).
2024-06-10 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of tentative approval from the USFDA for a pharmaceutical product. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations. The content is a corporate announcement about regulatory approval and does not contain financial statements, management discussion, or detailed financial data. The document length is 4312 characters, which is relatively short and typical for a press release or regulatory announcement. There is no indication that this is a full financial report, audit report, or earnings release. It is not a report publication announcement since it does not mention the release or availability of a report. The document fits best as a Regulatory Filing (RNS) because it is a regulatory disclosure about a material event (USFDA approval) that does not fit other specific categories like earnings, management changes, or capital updates.
2024-06-06 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details receipt of a Show Cause Notice (SCN) from the Goods and Service Tax (GST) Authority regarding a potential demand related to GST liabilities for the period 2019-2020. The document includes specifics of the alleged violations, the monetary impact, and the company's intended response. There are no financial statements or comprehensive financial data presented, nor is this a report or earnings release. The document is a regulatory announcement about a legal/tax matter affecting the company, which fits best under Regulatory Filings (RNS) as it does not fit other categories like Legal Proceedings Report (LTR) because it is a notice disclosure rather than an update on ongoing litigation. The document length is short (3327 characters), and it is not an announcement of a report publication but a direct disclosure under regulatory requirements.
2024-05-31 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details the receipt of a show cause notice (SCN) from the GST Authority regarding a tax demand for the fiscal period 2019-2020. The document includes specifics of the alleged violations and the company's intention to respond. The content is a regulatory announcement about a legal/tax matter, not a full report or financial statement. The document length is 3162 characters, which is relatively short and consistent with a regulatory filing or announcement. There is no financial data or comprehensive report content, so it does not qualify as an Annual Report, Interim Report, or Audit Report. It is not a certification or officer attestation document either. Therefore, the best fit is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2024-05-30 English
Copy of Newspaper Publication
Regulatory Filings
2024-05-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.